臨床眼科65巻9号

2011年09月発行

連載 今月の話題

酸化ストレスと眼疾患

著者： 谷戸正樹¹

所属機関： ¹島根大学医学部眼科学講座

ページ範囲：P.1383 - P.1393

文献概要

　酸化ストレスとは，生体内の高分子（脂質・蛋白質・核酸）が，酸化還元反応により修飾を受け，その機能が変化することである。臨床検体での酸化ストレスマーカー測定により，種々の眼疾患への酸化ストレスの関与が指摘されている。また，無作為化割付試験により，眼疾患への抗酸化治療の効果について知見が集積されつつある。

参考文献

1）谷戸正樹：眼と酸化ストレス；光ストレスを中心に．Pharma Medica　26（9）：19-23，2008

2）谷戸正樹・中村　肇・淀井淳司：C酸化ストレス関連マーカー/7．活性酸素種（ROS）．日本臨牀　62（増刊）：547-550，2004

3）A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss：AREDS report no. 8. Arch Ophthalmol　119：1417-1436, 2001

4）Babizhayev MA, Burke L, Micans P et al：N-Acetylcarnosine sustained drug delivery eye drops to control the signs of ageless vision：glare sensitivity, cataract amelioration and quality of vision currently available treatment for the challenging 50,000-patient population. Clin Interv Aging　4：31-50, 2009

5）Totan Y, Yagci R, Bardak Y et al：Oxidative macromolecular damage in age-related macular degeneration. Curr Eye Res　34：1089-1093, 2009

6）Ates O, Azizi S, Alp HH et al：Decreased serum paraoxonase 1 activity and increased serum homocysteine and malondialdehyde levels in age-related macular degeneration. Tohoku J Exp Med　217：17-22, 2009

7）Yamada Y, Tian J, Yang Y et al：Oxidized low density lipoproteins induce a pathologic response by retinal pigmented epithelial cells. J Neurochem　105：1187-1197, 2008

8）Ethen CM, Reilly C, Feng X et al：Age-related macular degeneration and retinal protein modification by 4-hydroxy-2-nonenal. Invest Ophthalmol Vis Sci　48：3469-3479, 2007

9）Kamei M, Yoneda K, Kume N et al：Scavenger receptors for oxidized lipoprotein in age-related macular degeneration. Invest Ophthalmol Vis Sci　48：1801-1807, 2007

10）Oz O, Aras Ates N, Tamer L et al：Glutathione S-transferase M1, T1, and P1 gene polymorphism in exudative age-related macular degeneration：a preliminary report. Eur J Ophthalmol　16：105-110, 2006

11）Baskol G, Karakucuk S, Oner AO et al：Serum paraoxonase 1 activity and lipid peroxidation levels in patients with age-related macular degeneration. Ophthalmologica　220：12-16, 2006

12）Coral K, Raman R, Rathi S et al：Plasma homocysteine and total thiol content in patients with exudative age-related macular degeneration. Eye（Lond）　20：203-207, 2006

13）Yildirim O, Ates NA, Tamer L et al：Changes in antioxidant enzyme activity and malondialdehyde level in patients with age-related macular degeneration. Ophthalmologica　218：202-206, 2004

14）Blasi MA, Bovina C, Carella G et al：Does coenzyme Q10 play a role in opposing oxidative stress in patients with age-related macular degeneration? Ophthalmologica　215：51-54, 2001

15）Frank RN, Amin RH, Puklin JE：Antioxidant enzymes in the macular retinal pigment epithelium of eyes with neovascular age-related macular degeneration. Am J Ophthalmol　127：694-709, 1999

16）Prashar S, Pandav SS, Gupta A et al：Antioxidant enzymes in RBCs as a biological index of age related macular degeneration. Acta Ophthalmol（Copenh）　71：214-218, 1993

17）Ni J, Yuan X, Gu J et al：Plasma protein pentosidine and carboxymethyllysine, biomarkers for age-related macular degeneration. Mol Cell Proteomics　8：1921-1933, 2009

18）Gu X, Meer SG, Miyagi M et al：Carboxyethylpyrrole protein adducts and autoantibodies, biomarkers for age-related macular degeneration. J Biol Chem　278：42027-42035, 2003

19）Glenn JV, Beattie JR, Barrett L et al：Confocal Raman microscopy can quantify advanced glycation end product（AGE）modifications in Bruch's membrane leading to accurate, nondestructive prediction of ocular aging. FASEB J　21：3542-3552, 2007

20）Turk A, Nuhoglu I, Mentese A et al：The relationship between diabetic retinopathy and serum levels of ischemia-modified albumin and malondialdehyde. Retina　31：602-608, 2011

21）Oettl K, Reibnegger G, Schmut O：The redox state of human serum albumin in eye diseases with and without complications. Acta Ophthalmol　89：e174-e179, 2011

22）Nowak M, Wielkoszynski T, Marek B et al：Antioxidant potential, paraoxonase 1, ceruloplasmin activity and C-reactive protein concentration in diabetic retinopathy. Clin Exp Med　10：185-192, 2010

23）Hovnik T, Dolzan V, Bratina NU et al：Genetic polymorphisms in genes encoding antioxidant enzymes are associated with diabetic retinopathy in type 1 diabetes. Diabetes Care　32：2258-2262, 2009

24）Margetis PI, Antonelou MH, Petropoulos IK et al：Increased protein carbonylation of red blood cell membrane in diabetic retinopathy. Exp Mol Pathol　87：76-82, 2009

25）Baskol G, Gumus K, Oner A et al：The role of advanced oxidation protein products and total thiols in diabetic retinopathy. Eur J Ophthalmol　18：792-798, 2008

26）Zhang X, Lai Y, McCance DR et al：Evaluation of N（epsilon）-（3-formyl-3,4-dehydropiperidino）lysine as a novel biomarker for the severity of diabetic retinopathy. Diabetologia　51：1723-1730, 2008

27）Dong QY, Cui Y, Chen L et al：Urinary 8-hydroxydeoxyguanosine levels in diabetic retinopathy patients. Eur J Ophthalmol　18：94-98, 2008

28）Petrovic MG, Cilensek I, Petrovic D：Manganese superoxide dismutase gene polymorphism（V16A）is associated with diabetic retinopathy in Slovene（Caucasians）type 2 diabetes patients. Dis Markers　24：59-64, 2008

29）Endo M, Yanagisawa K, Tsuchida K et al：Increased levels of vascular endothelial growth factor and advanced glycation end products in aqueous humor of patients with diabetic retinopathy. Horm Metab Res　33：317-322, 2001

30）Hartnett ME, Stratton RD, Browne RW et al：Serum markers of oxidative stress and severity of diabetic retinopathy. Diabetes Care　23：234-240, 2000

31）Hammes HP, Brownlee M, Lin J et al：Diabetic retinopathy risk correlates with intracellular concentrations of the glycoxidation product Nepsilon-（carboxymethyl）lysine independently of glycohaemoglobin concentrations. Diabetologia　42：603-607, 1999

32）Ghanem AA, Elewa A, Arafa LF：Pentosidine and N-carboxymethyl-lysine：biomarkers for type 2 diabetic retinopathy. Eur J Ophthalmol　21：48-54, 2011

33）Nakamura N, Hasegawa G, Obayashi H et al：Increased concentration of pentosidine, an advanced glycation end product, and interleukin-6 in the vitreous of patients with proliferative diabetic retinopathy. Diabetes Res Clin Pract　61：93-101, 2003

34）Miura J, Yamagishi S, Uchigata Y et al：Serum levels of non-carboxymethyllysine advanced glycation endproducts are correlated to severity of microvascular complications in patients with Type 1 diabetes. J Diabetes Complications　17：16-21, 2003

35）Matsumoto Y, Takahashi M, Chikuda M et al：Levels of mature cross-links and advanced glycation end product cross-links in human vitreous. Jpn J Ophthalmol　46：510-517, 2002

36）Beisswenger PJ, Makita Z, Curphey TJ et al：Formation of immunochemical advanced glycosylation end products precedes and correlates with early manifestations of renal and retinal disease in diabetes. Diabetes　44：824-829, 1995

37）McCance DR, Dyer DG, Dunn JA et al：Maillard reaction products and their relation to complications in insulin-dependent diabetes mellitus. J Clin Invest　91：2470-2478, 1993

38）Sell DR, Lapolla A, Odetti P et al：Pentosidine formation in skin correlates with severity of complications in individuals with long-standing IDDM. Diabetes　41：1286-1292, 1992

39）Ates O, Alp HH, Caner I et al：Oxidative DNA damage in retinopathy of prematurity. Eur J Ophthalmol　19：80-85, 2009

40）Tuson M, Garanto A, Gonzalez-Duarte R et al：Overexpression of CERKL, a gene responsible for retinitis pigmentosa in humans, protects cells from apoptosis induced by oxidative stress. Mol Vis　15：168-180, 2009

41）Field MG, Elner VM, Park S et al：Detection of retinal metabolic stress resulting from central serous retinopathy. Retina　29：1162-1166, 2009

42）Rajesh M, Sulochana KN, Coral K et al：Determination of carbonyl group content in plasma proteins as a useful marker to assess impairment in antioxidant defense in patients with Eales' disease. Indian J Ophthalmol　52：139-144, 2004

43）Srivastava P, Saxena S, Khanna VK et al：Raised platelet thiobarbituric acid-reacting substances in proliferative Eales' disease. Indian J Ophthalmol　48：307-309, 2000

44）Yen MY, Kao SH, Wang AG et al：Increased 8-hydroxy-2'-deoxyguanosine in leukocyte DNA in Leber's hereditary optic neuropathy. Invest Ophthalmol Vis Sci　45：1688-1691, 2004

45）Parikh JG, Saraswathy S, Rao NA：Photoreceptor oxidative damage in sympathetic ophthalmia. Am J Ophthalmol　146：866-875 e2, 2008

46）Yardim-Akaydin S, Sepici A, Ozkan Y et al：Evaluation of allantoin levels as a new marker of oxidative stress in Behcet's disease. Scand J Rheumatol　35：61-64, 2006

47）Bekpinar S, Kilic N, Unlucerci Y et al：Evaluation of nitrosative and oxidative stress in Behcet disease. J Eur Acad Dermatol Venereol　19：167-171, 2005

48）Yazici C, Kose K, Calis M et al：Increased advanced oxidation protein products in Behcet's disease：a new activity marker? Br J Dermatol　151：105-111, 2004

49）Erkilic K, Evereklioglu C, Cekmen M et al：Adenosine deaminase enzyme activity is increased and negatively correlates with catalase, superoxide dismutase and glutathione peroxidase in patients with Behcet's disease：original contributions/clinical and laboratory investigations. Mediators Inflamm　12：107-116, 2003

50）Majsterek I, Malinowska K, Stanczyk M et al：Evaluation of oxidative stress markers in pathogenesis of primary open-angle glaucoma. Exp Mol Pathol　90：231-237, 2011

51）Yuki K, Murat D, Kimura I et al：Increased serum total antioxidant status and decreased urinary 8-hydroxy-2'-deoxyguanosine levels in patients with normal-tension glaucoma. Acta Ophthalmol　88：e259-e264, 2010

52）Engin KN, Yemisci B, Yigit U et al：Variability of serum oxidative stress biomarkers relative to biochemical data and clinical parameters of glaucoma patients. Mol Vis　16：1260-1271, 2010

53）Izzotti A, Sacca SC, Longobardi M et al：Mitochondrial damage in the trabecular meshwork of patients with glaucoma. Arch Ophthalmol　128：724-730, 2010

54）Ghanem AA, Arafa LF, El-Baz A：Oxidative stress markers in patients with primary open-angle glaucoma. Curr Eye Res　35：295-301, 2010

55）Cumurcu T, Gunduz A, Ozyurt H et al：Increased oxidative stress in patients with pseudoexfoliation syndrome. Ophthalmic Res　43：169-172, 2010

56）Feilchenfeld Z, Yucel YH, Gupta N：Oxidative injury to blood vessels and glia of the pre-laminar optic nerve head in human glaucoma. Exp Eye Res　87：409-414, 2008

57）Fernandez-Durango R, Fernandez-Martinez A, Garcia-Feijoo J et al：Expression of nitrotyrosine and oxidative consequences in the trabecular meshwork of patients with primary open-angle glaucoma. Invest Ophthalmol Vis Sci　49：2506-2511, 2008

58）Yagci R, Ersoz I, Erdurmus M et al：Protein carbonyl levels in the aqueous humour and serum of patients with pseudoexfoliation syndrome. Eye（Lond）　22：128-131, 2008

59）Sacca SC, Pascotto A, Camicione P et al：Oxidative DNA damage in the human trabecular meshwork：clinical correlation in patients with primary open-angle glaucoma. Arch Ophthalmol　123：458-463, 2005

60）Yildirim O, Ates NA, Ercan B et al：Role of oxidative stress enzymes in open-angle glaucoma. Eye（Lond）　19：580-583, 2005

61）Ferreira SM, Lerner SF, Brunzini R et al：Oxidative stress markers in aqueous humor of glaucoma patients. Am J Ophthalmol　137：62-69, 2004

62）Koliakos GG, Konstas AG, Schlotzer-Schrehardt U et al：8-Isoprostaglandin F2a and ascorbic acid concentration in the aqueous humour of patients with exfoliation syndrome. Br J Ophthalmol　87：353-356, 2003

63）Babizhayev MA, Vishnyakova KS, Yegorov YE：Telomere-dependent senescent phenotype of lens epithelial cells as a biological marker of aging and cataractogenesis：the role of oxidative stress intensity and specific mechanism of phospholipid hydroperoxide toxicity in lens and aqueous. Fundam Clin Pharmacol　25：139-162, 2011

64）Ates O, Alp HH, Kocer I et al：Oxidative DNA damage in patients with cataract. Acta Ophthalmol　88：891-895, 2010

65）Sawada H, Fukuchi T, Abe H：Oxidative stress markers in aqueous humor of patients with senile cataracts. Curr Eye Res　34：36-41, 2009

66）Li L, Duker JS, Yoshida Y et al：Oxidative stress and antioxidant status in older adults with early cataract. Eye（Lond）　23：1464-1468, 2009

67）Virgolici B, Stoian I, Muscurel C et al：Plasma redox status and premature onset of senile cataract. Rom J Intern Med　45：59-65, 2007

68）Hashim Z, Zarina S：Assessment of paraoxonase activity and lipid peroxidation levels in diabetic and senile subjects suffering from cataract. Clin Biochem　40：705-709, 2007

69）Chandrasena LG, Chackrewarthy S, Perera PT et al：Erythrocyte antioxidant enzymes in patients with cataract. Ann Clin Lab Sci　36：201-204, 2006

70）Tarwadi K, Agte V：Linkages of antioxidant, micronutrient, and socioeconomic status with the degree of oxidative stress and lens opacity in indian cataract patients. Nutrition　20：261-267, 2004

71）Ahmed N, Thornalley PJ, Dawczynski J et al：Methylglyoxal-derived hydroimidazolone advanced glycation end-products of human lens proteins. Invest Ophthalmol Vis Sci　44：5287-5292, 2003

72）Franke S, Dawczynski J, Strobel J et al：Increased levels of advanced glycation end products in human cataractous lenses. J Cataract Refract Surg　29：998-1004, 2003

73）Franke S, Stein F, Dawczynski J et al：Advanced glycation end-products in anterior chamber aqueous of cataractous patients. J Cataract Refract Surg　29：329-335, 2003

74）Donma O, Yorulmaz E, Pekel H et al：Blood and lens lipid peroxidation and antioxidant status in normal individuals, senile and diabetic cataractous patients. Curr Eye Res　25：9-16, 2002

75）Wakamatsu TH, Dogru M, Ayako I et al：Evaluation of lipid oxidative stress status and inflammation in atopic ocular surface disease. Mol Vis　16：2465-2475, 2010

76）Jurkunas UV, Bitar MS, Funaki T et al：Evidence of oxidative stress in the pathogenesis of fuchs endothelial corneal dystrophy. Am J Pathol　177：2278-2289, 2010

77）Kau HC, Tsai CC, Lee CF et al：Increased oxidative DNA damage, 8-hydroxydeoxy-guanosine, in human pterygium. Eye（Lond）　20：826-831, 2006

78）Tsai YY, Cheng YW, Lee H et al：Oxidative DNA damage in pterygium. Mol Vis　11：71-75, 2005

79）Kaji Y, Nagai R, Amano S et al：Advanced glycation end product deposits in climatic droplet keratopathy. Br J Ophthalmol　91：85-88, 2007

80）Kaji Y, Oshika T, Amano S et al：Immunohistochemical localization of advanced glycation end products in pinguecula. Graefes Arch Clin Exp Ophthalmol　244：104-108, 2006

81）Wong WT, Kam W, Cunningham D et al：Treatment of geographic atrophy by the topical administration of OT-551：results of a phase Ⅱ clinical trial. Invest Ophthalmol Vis Sci　51：6131-6139, 2010

82）Christen WG, Glynn RJ, Sesso HD et al：Age-related cataract in a randomized trial of vitamins E and C in men. Arch Ophthalmol　128：1397-1405, 2010

83）Saxena S, Srivastava P, Khanna VK：Antioxidant supplementation improves platelet membrane fluidity in idiopathic retinal periphlebitis（Eales' disease）. J Ocul Pharmacol Ther　26：623-626, 2010

84）Falsini B, Piccardi M, Minnella A et al：Influence of saffron supplementation on retinal flicker sensitivity in early age-related macular degeneration. Invest Ophthalmol Vis Sci　51：6118-6124, 2010

85）Akyol-Salman I, Azizi S, Mumcu U et al：Efficacy of topical N-acetylcysteine in the treatment of meibomian gland dysfunction. J Ocul Pharmacol Ther　26：329-333, 2010

86）Hirano T, Kawai M, Arimitsu J et al：Preventative effect of a flavonoid, enzymatically modified isoquercitrin on ocular symptoms of Japanese cedar pollinosis. Allergol Int　58：373-382, 2009

87）Goldblum D, Meyenberg A, Mojon D et al：Dietary tocopherol supplementation after trabeculectomy and phacotrabeculectomy：double-blind randomized placebo-controlled trial. Ophthalmologica　223：228-232, 2009

88）Christen WG, Glynn RJ, Chew EY et al：Folic acid, pyridoxine, and cyanocobalamin combination treatment and age-related macular degeneration in women：the Women's Antioxidant and Folic Acid Cardiovascular Study. Arch Intern Med　169：335-341, 2009

89）Cangemi FE：TOZAL Study：an open case control study of an oral antioxidant and omega-3 supplement for dry AMD. BMC Ophthalmol　7：3, 2007

90）Sharquie KE, Najim RA, Al-Dori WS et al：Oral zinc sulfate in the treatment of Behcet's disease：a double blind cross-over study. J Dermatol　33：541-546, 2006

91）Gritz DC, Srinivasan M, Smith SD et al：The Antioxidants in Prevention of Cataracts Study：effects of antioxidant supplements on cataract progression in South India. Br J Ophthalmol　90：847-851, 2006

92）Christen W, Glynn R, Sperduto R et al：Age-related cataract in a randomized trial of beta-carotene in women. Ophthalmic Epidemiol　11：401-412, 2004

93）Berson EL, Rosner B, Sandberg MA et al：Further evaluation of docosahexaenoic acid in patients with retinitis pigmentosa receiving vitamin A treatment：subgroup analyses. Arch Ophthalmol　122：1306-1314, 2004

94）Berson EL, Rosner B, Sandberg MA et al：Clinical trial of docosahexaenoic acid in patients with retinitis pigmentosa receiving vitamin A treatment. Arch Ophthalmol　122：1297-1305, 2004

95）Richer S, Stiles W, Statkute L et al：Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration：the Veterans LAST study（Lutein Antioxidant Supplementation Trial）. Optometry　75：216-230, 2004

96）McNeil JJ, Robman L, Tikellis G et al：Vitamin E supplementation and cataract：randomized controlled trial. Ophthalmology　111：75-84, 2004

97）Pasantes-Morales H, Quiroz H, Quesada O：Treatment with taurine, diltiazem, and vitamin E retards the progressive visual field reduction in retinitis pigmentosa：a 3-year follow-up study. Metab Brain Dis　17：183-197, 2002

98）Taylor HR, Tikellis G, Robman LD et al：Vitamin E supplementation and macular degeneration：randomised controlled trial. BMJ　325：11, 2002

99）A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E and beta carotene for age-related cataract and vision loss：AREDS report no. 9. Arch Ophthalmol　119：1439-1452, 2001

100）Seth RK, Kharb S：Protective function of alpha-tocopherol against the process of cataractogenesis in humans. Ann Nutr Metab　43：286-289, 1999

101）Teikari JM, Rautalahti M, Haukka J et al：Incidence of cataract operations in Finnish male smokers unaffected by alpha tocopherol or beta carotene supplements. J Epidemiol Community Health　52：468-472, 1998

102）Teikari JM, Laatikainen L, Virtamo J et al：Six-year supplementation with alpha-tocopherol and beta-carotene and age-related maculopathy. Acta Ophthalmol Scand　76：224-229, 1998

103）Teikari JM, Virtamo J, Rautalahti M et al：Long-term supplementation with alpha-tocopherol and beta-carotene and age-related cataract. Acta Ophthalmol Scand　75：634-640, 1997

104）Richer S：Multicenter ophthalmic and nutritional age-related macular degeneration study-part 2：antioxidant intervention and conclusions. J Am Optom Assoc　67：30-49, 1996

105）Phelps DL, Rosenbaum AL, Isenberg SJ et al：Tocopherol efficacy and safety for preventing retinopathy of prematurity：a randomized, controlled, double-masked trial. Pediatrics　79：489-500, 1987

106）Walters MT, Rubin CE, Keightley SJ et al：A double-blind, cross-over, study of oral N-acetylcysteine in Sjogren's syndrome. Scand J Rheumatol Suppl　61：253-258, 1986

107）Schaffer DB, Johnson L, Quinn GE et al：Vitamin E and retinopathy of prematurity. Follow-up at one year. Ophthalmology　92：1005-1011, 1985

108）Finer NN, Schindler RF, Grant G et al.：Effect of intramuscular vitamin E on frequency and severity of retrolental fibroplasia. A controlled trial. Lancet　1：1087-1091, 1982